New tapered @entity1702 for unresectable malignant hilar XXXX .

@entity1 @entity1126 @entity1702 @entity1448 @entity1086 @entity850
AIM: To examine the usefulness of a new tapered @entity1702 ( @entity1702 ) in @entity1 with unresectable malignant hilar @entity1448 . METHODS: This new tapered @entity1702 was placed in 11 @entity1 with Bismuth II or severer unresectable malignant hilar @entity1448 , as a prospective study. The subjects were six @entity1 with @entity1126 , three with @entity1086 , and two with metastatic @entity1448 . @entity850 morphology was Bismuth II: 7, IIIa: 3, and IV: 1. UMIN Clinical Trial Registry (UMIN000004758). RESULTS: @entity1702 placement was 100% (11/11) successful. There were no procedural accidents. The mean patency period was 208.401 d, the median survival period was 142.000 d, and the mean survival period was 193.273 d. Occlusion rate was 36.4% (4/11); the causes of occlusion were ingrowth and overgrowth in 2 @entity1 each, 18.2%, respectively. @entity1 with occlusion underwent endoscopic treatment one more time and all were treatable. CONCLUSION: The tapered @entity1702 proved useful in @entity1 with unresectable malignant hilar @entity1448 because it provided a long patency period, enabled re-treatment by re-intervention, and no procedural accidents occurred.
